the questions, answered honestly
CJC-1295 FAQ: safety, side effects, and straight answers
The questions readers actually ask — about safety, the DAC chemistry, testosterone, and FDA status — each answered in a sentence or two, with the honest gaps marked.
Safety and side effects
These questions get the careful-daisy treatment first, because the safety record is where a "safe" reading has to be most honest.
Is CJC-1295 safe?
There is no adequate long-term human safety data; CJC-1295 is unapproved. Theoretical and documented concerns include fluid retention and edema (growth hormone increases renal sodium reabsorption), modestly increased cancer-risk signals tied to sustained IGF-1 elevation [7], and immunogenicity flagged by the FDA [9]. It is not approved for human use anywhere.
Are CJC-1295 peptides safe?
No long-term human safety data establish this. The published human record is limited to short early pharmacokinetic studies [1]; sustained GH/IGF-1 elevation carries theoretical risks including fluid retention and the IGF-1/cancer-risk epidemiology [7], and the FDA has cited immunogenicity concerns for GH secretagogues including CJC-1295 [9].
Documented and Theoretical Side Effects of CJC-1295
Reported and theoretical CJC-1295 side effects center on GH-axis stimulation: fluid retention and edema (growth hormone increases renal sodium reabsorption), effects on insulin sensitivity, and — from sustained IGF-1 elevation — the cancer-risk signal seen in IGF-1 epidemiology [7]. The FDA has also flagged immunogenicity [9]. None of this comes from a long-term safety trial, because none exists.
What are the side effects of CJC-1295?
Reported and theoretical concerns center on GH-axis stimulation: fluid retention and edema (growth hormone increases renal sodium reabsorption), effects on insulin sensitivity, and — from sustained IGF-1 elevation — the cancer-risk signal seen in IGF-1 epidemiology [7]. The FDA has flagged immunogenicity among its concerns [9].
What it is and what it does
Is CJC-1295 a steroid?
No. It is a peptide — a synthetic GHRH analog that acts upstream on the pituitary to release the body's own growth hormone [2]. It is not an anabolic-androgenic steroid and does not act on androgen receptors.
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved for human use by the FDA or any major regulator and is handled as a research chemical [1]. At the 2024 FDA Pharmacy Compounding Advisory Committee it was reviewed and not recommended for the 503A compounding bulks list, with immunogenicity cited among the concerns [9].
Hormones and comparisons
Does CJC-1295 affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the androgen axis; the published studies measure growth hormone and IGF-1, not testosterone [3]. There is no controlled human evidence that it raises or lowers testosterone.
Does CJC-1295 lower testosterone?
No controlled human study shows CJC-1295 lowering testosterone; it acts on the GH/IGF-1 axis rather than the gonadal axis [3], and the published trials did not track testosterone as an endpoint.
Are peptides safer than TRT?
Not an answerable equivalence: testosterone-replacement therapy is an approved, monitored treatment with extensive data, whereas CJC-1295 is an unapproved research chemical with only short early-phase human pharmacokinetic data [1]. The closest approved GHRH-analog comparator is tesamorelin, studied in HIV-associated fat accumulation [6].
Regulation, sport, and the two forms
A short cluster on the questions that decide whether a careful reader should engage with this compound at all.
Is CJC-1295 banned in sport?
Yes. CJC-1295 is prohibited at all times under Section S2 of the WADA Prohibited List (peptide hormones and growth factors) and is banned by bodies including the NCAA. It has been identified in seized preparations by LC-MS/MS [8], and detection assays for it are well established — so for any tested athlete the answer is unambiguous.
Was CJC-1295 ever in clinical trials?
Yes, briefly. Early-phase human pharmacokinetic studies established its GH/IGF-1 kinetics [1][3], and a ConjuChem Phase 2 program in HIV-associated visceral obesity was run — but that program was discontinued and the long-acting DAC development did not advance [1]. No large efficacy or long-term safety trial in healthy adults was ever completed.
Why are CJC-1295 and Modified GRF 1-29 confused?
Because they share the same tetrasubstituted hGRF(1-29) backbone and differ only in the albumin-binding DAC handle. That one difference makes the DAC form last days and the no-DAC form last minutes to hours [1], so conflating them is a real pharmacokinetic error — covered in full on the DAC vs no-DAC page.